Skip to Content

Generic Proscar Availability

Proscar is a brand name of finasteride, approved by the FDA in the following formulation(s):

PROSCAR (finasteride - tablet;oral)

  • Manufacturer: MERCK
    Approval date: June 19, 1992
    Strength(s): 5MG [RLD] [AB]

Has a generic version of Proscar been approved?

A generic version of Proscar has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Proscar and have been approved by the FDA:

finasteride tablet;oral

  • Manufacturer: ACCORD HLTHCARE
    Approval date: February 23, 2010
    Strength(s): 5MG [AB]
  • Manufacturer: ACTAVIS TOTOWA TEVA
    Approval date: March 28, 2007
    Strength(s): 5MG [AB]
  • Manufacturer: ALKEM LABS LTD
    Approval date: January 5, 2017
    Strength(s): 5MG [AB]
  • Manufacturer: AUROBINDO PHARMA
    Approval date: October 30, 2007
    Strength(s): 5MG [AB]
  • Manufacturer: DR REDDYS LABS LTD
    Approval date: February 28, 2007
    Strength(s): 5MG [AB]
  • Manufacturer: GEDEON RICHTER USA
    Approval date: December 22, 2006
    Strength(s): 5MG [AB]
  • Manufacturer: HETERO LABS LTD III
    Approval date: June 7, 2010
    Strength(s): 5MG [AB]
  • Manufacturer: MYLAN
    Approval date: December 18, 2006
    Strength(s): 5MG [AB]
  • Manufacturer: SUN PHARMA GLOBAL
    Approval date: August 16, 2011
    Strength(s): 5MG [AB]
  • Manufacturer: TEVA
    Approval date: December 15, 2006
    Strength(s): 5MG [AB]
  • Manufacturer: ZYDUS PHARMS USA INC
    Approval date: December 28, 2009
    Strength(s): 5MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Proscar. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Prevention of precipitated acute urinary retention
    Patent 5,942,519
    Issued: August 24, 1999
    Inventor(s): Waldstreicher; Joanne
    Assignee(s): Merck & Co., Inc.
    This invention is concerned with the prevention of precipitated acute urinary retention in a subject male susceptible thereto by the administration of an inhibitor of 5.alpha.-reductase to the subject. The present invention also provides for a method of reducing the risk of precipitated acute urinary retention by the administration of a 5.alpha.-reductase inhibitor to the subject at risk therefor.
    Patent expiration dates:
    • October 23, 2018
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.